Immunogenicity With Ranibizumab Biosimilar SB11 (Byooviz) and Reference Product Lucentis and Association With Efficacy, Safety, and Pharmacokinetics: A Post Hoc Analysis of a Phase 3 Randomized Clinical Trial.

导出 LinkOut

翻译打印收藏纠错

作者： Neil M,Bressler ^[1] ; Taehyung,Kim ^[2] ; Inkyung,Oh ^[3] ; Paola,Russo ^[3] ; Mercy Yeeun,Kim ^[3] ; Se Joon,Woo ^[3]

作者单位： Department of Ophthalmology, Johns Hopkins University School of Medicine, Baltimore, Maryland. ^[1] Editor, JAMA Ophthalmology. ^[2] Samsung Bioepis, Incheon, Republic of Korea. ^[3] Department of Ophthalmology, Seoul National University College of Medicine, Seoul National University Bundang Hospital, Seongnam, Republic of Korea. ^[4]

主题词人类(Humans);女(雌)性(Female);老年人(Aged);血管生成抑制剂(Angiogenesis Inhibitors);治疗结果(Treatment Outcome);玻璃体内注射(Intravitreal Injections);炎症(Inflammation)

DOI 10.1001/jamaophthalmol.2022.5403

PMID 36520462

发布时间 2023-03-06

翻译满意度评价：

准确一般字义偏差语意偏离译文作用小提交

浏览1

JAMA ophthalmology

2023年141卷2期

117-127页

相似文献

中文期刊
外文期刊
学位论文
会议论文

检索历史清除

Immunogenicity With Ranibizumab Biosimilar SB11 (Byooviz) and Reference Product Lucentis and Association With Efficacy, Safety, and Pharmacokinetics: A Post Hoc Analysis of a Phase 3 Randomized Clinical Trial.

JAMA ophthalmology

相似文献

JAMA ophthalmology

相关期刊

参考文献：
指定格式：	NoteExpress EndNote RefWorks NoteFirst

检索历史 清除

Immunogenicity With Ranibizumab Biosimilar SB11 (Byooviz) and Reference Product Lucentis and Association With Efficacy, Safety, and Pharmacokinetics: A Post Hoc Analysis of a Phase 3 Randomized Clinical Trial.

JAMA ophthalmology

相似文献

JAMA ophthalmology

相关期刊

检索历史清除